Mathew Palmer, Chief Growth and Commercial Officer, will be in Switzerland THIS WEEK!
Accelagen is proud to announce an exciting collaboration with Crux Biolabs, Veritus Clinical Research, and RDI Partners, as they join forces to showcase the Australian Advantage at Swiss Biotech Day 2025 in Basel, Switzerland, 5-6 May.
This marks a major milestone for Accelagen—and for Australia’s rapidly growing biotech sector—as the companies present a unified front under the “Team Australia” banner. Together, they will illustrate why Australia has become one of the smartest, most efficient choices for international companies advancing early-phase clinical development.
A Unique Collaboration at Swiss Biotech Day
Throughout the week, Accelagen’s Mathew Palmer and other Australian representatives will first be participating in partnering meetings and booth exhibits during the Basel portion of the conference. They will then head to Zurich for a special panel session where they will highlight how Australia’s tightly integrated clinical trial, bioanalytical, and R&D incentive ecosystem provides critical advantages for biotech innovators around the world.
As Mathew explained, “We wanted to bring together a group of people who work closely in Australia’s ecosystem—from clinical operations and CRO services to bioanalytics, R&D tax expertise, and clinical site management. Together, we present a complete solution for companies looking to transition efficiently from preclinical studies to first-in-human trials.”
Why Switzerland? Why Now?
Switzerland’s vibrant biotech industry—marked by its entrepreneurial spirit and innovation focus—makes it an ideal location to share the benefits of starting development programs in Australia. As European companies look for ways to accelerate timelines, control costs, and manage regulatory complexity, the Australian model offers real-world advantages:
- Streamlined Ethics and Regulatory Processes: Unlike in the US or Europe, Australia’s system allows clinical trials to be approved quickly by ethics committees without requiring full IND or CTA submissions, cutting months off development timelines.
- Cost Advantages through the R&D Tax Incentive Scheme: With up to a 43.5% rebate on eligible clinical trial expenses, companies investing in Australia can stretch their R&D budgets further.
- High-Quality, Globally Accepted Data: Australia’s clinical trial infrastructure delivers results that are recognized by regulatory agencies around the world.
Mathew notes, “For growing biotech companies, timelines, quality, and cost predictability are crucial. The Australian model gives emerging companies more control, allowing them to avoid delays and cost overruns that can derail future funding and success.”
Who Should Attend the Panel?
The panel discussion in Zurich is designed for biotech and pharmaceutical leaders involved in early development decisions—from preclinical through Phase I and beyond. Whether you’re an emerging biotech exploring global clinical strategies, or an established company seeking ways to maximize investment and efficiency, you’ll gain valuable insights into how the Australian ecosystem can drive your success.
Meet the Team at Swiss Biotech Day
During Swiss Biotech Day in Basel, you can find the Accelagen, Crux Biolabs, Veritas, and RDI teams in the Global Village, booth CC23—the “Team Australia” booth. They are also available for 1:1 partnering meetings through the conference partnering system.
Attendees visiting the booth can meet representatives from:
- Accelagen: Clinical trial execution and CRO services
- Crux Biolabs: Bioanalytical testing and laboratory support
- Veritas Research: Clinical trial site management
- RDI Partners: R&D tax incentive consulting
Together, this integrated group offers biotech companies a full-service, cost-effective pathway to early clinical success—all while tapping into the benefits of operating in one of the world’s most dynamic R&D environments.
Want to Learn More?
If you’re attending Swiss Biotech Day or will be nearby in Zurich, reach out to Mathew Palmer or visit the booth to schedule a meeting. This is a unique opportunity to connect with a cross-functional team ready to help companies navigate the critical early stages of development—with precision, speed, and strategic foresight.
Join us at Swiss Biotech Day—and discover the Australian Advantage.